Guardant Health Release: Leading Cancer Centers To Present Clinical Utility Data For Guardant360 At ASCO

REDWOOD CITY, Calif., May 27, 2015 /PRNewswire/ -- Guardant Health® today announced that five abstracts submitted by the University of California, San Francisco; University of California, San Diego; and MD Anderson highlighting the performance and clinical utility of Guardant360® have been accepted for oral and poster presentations at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 29-June 2.

The company will also unveil several groundbreaking analytical tools for Guardant360, its biopsy-free cancer blood test. This toolset includes:

• Tumor Response Map: A powerful new visual language of tumor genomics, helping to unify the representation of tumor genomics, heterogeneity and clinical response over time.
• Enhanced Guardant360 Report: By using the Tumor Response Map and the alteration-specific trend line, the report offers a visual representation of changes and trends in patients' sequential tests, allowing them to quickly see a summary of all detected somatic cfDNA alterations and their quantitative burden, along with available therapeutics and clinical trials.
• Guardant360 Portal: A mobile-enabled Physician Portal fueled by the Tumor Response Map that enables easy-to-use dynamic tracking of a patient's tumor genomics data and associated treatment options.

Today's news continues Guardant Health's momentum in the marketplace. In less than one year, the company has conducted nearly 5,000 Guardant360 tests on multiple cancer types, with a faster adoption rate than other companies at this stage. In April, Guardant Health presented findings for more than 2,000 clinical patient samples highlighting a specificity rate at greater than 99.9999 percent. A recent MD Anderson Cancer Center study for metastatic colorectal cancer demonstrated higher quality of care for patients using Guardant360. Several institutions including UC San Francisco, Thomas Jefferson University and the University of Pennsylvania have collaborated with Guardant Health to demonstrate clinical utility of its test.

"In a year, we have made strong progress in the collaboration with partners, the clinical utility, and adoption of Guardant360," said Helmy Eltoukhy, co-founder and CEO of Guardant Health. "With the launch of our new tools and the data from our collaborators' upcoming presentations at ASCO, we expect to give oncologists and their patients unprecedented control over the management of their cancers."

Numerous leading oncologists are currently using Guardant360 to identify emerging tumor genomic alterations and unlock potentially overlooked treatment options for their patients. The data presented at ASCO will highlight the clinical utility of Guardant360 for solid tumor cancers on more than 3,000 patients, such as colorectal and pancreatic cancers, as well as detail its performance in tracking clinical response over standard serum protein markers.   

With only two vials of blood, Guardant360 digitally sequences billions of genomic data points to identify tumor genomic alterations at greater than 99.9999 percent specificity. These alterations are critical for clinical decisions and are reported in about half the turnaround time and with none of the risk of tissue biopsies. The Guardant360 platform gives oncologists and patients a simpler, faster and more accurate perspective of their treatment options, resulting in targeted therapies for genomic alterations.

The schedule of oral presentations:

Date and Time:  9:45 a.m.-11:15 a.m. CT, Monday June 1
Session Name: New Diagnostics: When Actionable is Objectionable
Subject: Prospective evaluation of circulating tumor DNA sequencing in pancreatobiliary carcinomas
Session Type: Clinical Science Symposium
Location: E Hall D1
Abstract: #107 from 10:35 a.m.-10:50 a.m.
Presenter: Eric Andrew Collisson, MD, UC San Francisco

Date and Time: 3:00 p.m.-6:00 p.m. CT, Monday June 1
Session Name: Tumor Biology
Subject: Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor DNA assay
Session Type: Oral Abstract Session
Location: E450
Abstract: #11004 from 4:12 pm - 4:24 pm
Presenter: Razelle Kurzrock, MD,UC San Diego Moores Cancer Center

The schedule of poster presentations:

Date and Time: 8:00 a.m.-11:30 a.m. CT Sunday, May 31
Title:  Analysis of cell-free circulating tumor DNA in patients with glioblastoma and other primary brain tumors
Abstract:  #11072
Location:  S Hall A
Poster Board Number: 286
Presenters:  David Eric Piccioni, MD, PhD, UC San Diego Moores Cancer Center

Date and Time: 8:00 a.m.-11:30 a.m. CT, Monday, June 1
Title:  Predictors of clonal evolution in metastatic colorectal cancer patients
Abstract:  #3604
Location:  S Hall A
Poster Board Number: 97
Presenters:  Maria Pia Morelli, MD, PhD, MD Anderson Cancer Center, Houston, TX

Date and Time:  8:00 a.m.-11:30 a.m. CT, Monday, June 1
Title:  Clinical utility of a circulating cell-free DNA assay for clinical trial enrollment in refractory metastatic colorectal cancer patients.
Abstract:  3601
Location:  S Hall A
Poster Board Number:  94
Presenters:  Van Karlyle Morris, MD, MD Anderson

Industry Expert Theater

Date and Time:  11:30 a.m.-12:30 p.m. CT, Sunday, May 31
Subject:  Guardant360: Demonstrating the Clinical Impact of Biopsy-free Tumor Sequencing on 3000+ Patients
Session Type: Industry Expert Theater
Location: Back of the Oncology Professionals Hall
Presenter:  Rick Lanman, MD, Guardant Health

Guardant Health is also an exhibitor at the 2015 ASCO Annual Meeting. Company representatives will be available to provide additional information on Guardant Health and its product, Guardant360, at the company's booth, #21140. To learn more, visit www.guardanthealth.com.

About Guardant Health

Guardant Health, headquartered in Redwood City, Calif., is focused on developing breakthrough diagnostics that can transform cancer from a silent killer into a manageable disease. Guardant Health was founded in 2012 by a team of serial entrepreneurs with expertise in next-generation sequencing, single-cell genomics and cancer diagnostics. The company has raised $100 million in funding from leading venture capital firms and its first product, Guardant360, came to market in 2014. The team is committed to positively and significantly impacting patient health through technology that addresses long-standing unmet needs in oncology. 

Media Contact:
Mark de la Vina
Consort Partners for Guardant Health
Email:  guardanthealth@consortpartners.com 
Phone:  415-282-4795

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/leading-cancer-centers-to-present-clinical-utility-data-for-guardant360-at-asco-300089231.html

SOURCE Guardant Health